col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


139 Results       Page 1

 [1] 
MDPI AG: Pharmaceuticals
  original article Date Title Authors   All Authors
1 [GO] 2022―Dec―05 Update on COVID-19 Therapy in Pediatric Age Susanna Esposito, Giovanni Autore, Alberto Argentiero, Greta Ramundo, Serafina Perrone, Nicola Principi
2 [GO] 2022―Nov―28 Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19 Jingrui Zou, Fuyuan Jing
3 [GO] 2022―Nov―24 Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir Bandar Alosaimi, Huda M. Alshanbari, Muath Alturaiqy, Halah Z. AlRawi, Saad Alamri, Asma Albujaidy, et al. (+7)
4 [GO] 2022―Nov―22 SARS-CoV-2 Inhibitors Identified by Phenotypic Analysis of a Collection of Viral RNA-Binding Molecules Alvaro Simba-Lahuasi, Ángel Cantero-Camacho, Romel Rosales, Briana Lynn McGovern, M. Luis Rodríguez, Vicente Marchán, et al. (+3)
5 [GO] 2022―Nov―11 Can Essential Oils Provide an Alternative Adjuvant Therapy for COVID-19 Infections and Pain Management at the Same Time? Roxana Damiescu, David Y. W. Lee, Thomas Efferth
6 [GO] 2022―Nov―08 Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19 Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Sarah M. Albogami, Sabatier Jean-Marc, Eman Hassan Nadwa, Amin A. Hafiz, et al. (+6)
7 [GO] 2022―Oct―30 Hybrid Approach to Identifying Druglikeness Leading Compounds against COVID-19 3CL Protease Imra Aqeel, Muhammad Bilal, Abdul Majid, Tuba Majid
8 [GO] 2022―Oct―24 An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice Dania O. Govea-Alonso, Ashwini Malla, Omayra C. Bolaños-Martínez, Sornkanok Vimolmangkang, Sergio Rosales-Mendoza
9 [GO] 2022―Sep―26 Pelargonium sidoides Root Extract: Simultaneous HPLC Separation, Determination, and Validation of Selected Biomolecules and Evaluation of SARS-CoV2 Inhibitory Activity Manal A. Alossaimi, May A. Alzeer, Fatma M. Abdel Bar, Mai H. ElNaggar
10 [GO] 2022―Aug―31 Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction from a Chemical Space of Privileged Protein Binders Sung-Ting Chuang, Peter Buchwald
11 [GO] 2022―Aug―30 Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19 Hoda Awad, Basmala Hassan, Sara Dweek, Yasmeen Aboelata, Mutasem Rawas-Qalaji, Iman Saad Ahmed
12 [GO] 2022―Aug―30 Real-World Use of Molnupiravir in the Treatment of Outpatients with SARS-CoV-2 Infection-A Patient Profile Based on the Experience of a Tertiary Infectious Disease Center Anca Streinu-Cercel, Victor Daniel Miron, Alina Alexandra Oană, Mădălina Irimia, Ramona Ștefania Popescu, Ioana Andreea Dărămuș, et al. (+3)
13 [GO] 2022―Aug―26 Quercetin in the Prevention and Treatment of Coronavirus Infections: A Focus on SARS-CoV-2 Amin Gasmi, Pavan Kumar Mujawdiya, Roman Lysiuk, Mariia Shanaida, Massimiliano Peana, Asma Gasmi Benahmed, et al. (+3)
14 [GO] 2022―Aug―25 Plant Metabolites as SARS-CoV-2 Inhibitors Candidates: In Silico and In Vitro Studies Alberto Jorge Oliveira Lopes, Gustavo Pereira Calado, Yuri Nascimento Fróes, Sandra Alves de Araújo, Lucas Martins França, Antonio Marcus de Andrade Paes, et al. (+3)
15 [GO] 2022―Aug―19 A Versatile Class of 1,4,4-Trisubstituted Piperidines Block Coronavirus Replication In Vitro Sonia De Castro, Annelies Stevaert, Miguel Maldonado, Adrien Delpal, Julie Vandeput, Benjamin Van Loy, et al. (+8)
16 [GO] 2022―Aug―18 Efficacy of Kan Jang® in Patients with Mild COVID-19: Interim Analysis of a Randomized, Quadruple-Blind, Placebo-Controlled Trial Levan Ratiani, Elene Pachkoria, Nato Mamageishvili, Ramaz Shengelia, Areg Hovhannisyan, Alexander Panossian
17 [GO] 2022―Aug―11 Search for Novel Potent Inhibitors of the SARS-CoV-2 Papain-like Enzyme: A Computational Biochemistry Approach Manuel I. Osorio, Osvaldo Yáñez, Mauricio Gallardo, Matías Zuñiga-Bustos, Jorge Mulia-Rodríguez, Roberto López-Rendón, et al. (+3)
18 [GO] 2022―Aug―04 Identification of a Dual Inhibitor of Secreted Phospholipase A2 (GIIA sPLA2) and SARS-CoV-2 Main Protease Maria A. Theodoropoulou, Giorgos S. Koutoulogenis, Linlin Zhang, Ifigeneia Akrani, Emmanuel Mikros, Rolf Hilgenfeld, George Kokotos
19 [GO] 2022―Jul―25 Impaired Vitamin D Metabolism in Hospitalized COVID-19 Patients Alexandra Povaliaeva, Viktor Bogdanov, Ekaterina Pigarova, Larisa Dzeranova, Nino Katamadze, Natalya Malysheva, et al. (+4)
20 [GO] 2022―Jul―14 Synthesis and Biological Evaluation of Imadazo[1,2-a]pyrazines as Anticancer and Antiviral Agents through Inhibition of CDK9 and Human Coronavirus Aisha A. Alsfouk, Hanan M. Alshibl, Bshra A. Alsfouk, Najla A. Altwaijry, Ebtehal S. Al-Abdullah
21 [GO] 2022―Jul―05 Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties Young Sup Shin, Jun Young Lee, Sangeun Jeon, Jung-Eun Cho, Subeen Myung, Min Seong Jang, et al. (+6)
22 [GO] 2022―Jun―27 The Potential Complementary Role of Using Chinese Herbal Medicine with Western Medicine in Treating COVID-19 Patients: Pharmacology Network Analysis Yi-Chin Lu, Liang-Wei Tseng, Yu-Chieh Huang, Ching-Wei Yang, Yu-Chun Chen, Hsing-Yu Chen
23 [GO] 2022―Jun―24 Biologics in COVID-19 So Far: Systematic Review Milton Arias, Henry Oliveros, Sharon Lechtig, Rosa-Helena Bustos
24 [GO] 2022―Jun―17 Effect of Norelgestromin and Ethinylestradiol in Transdermal Patches on the Clinical Outcomes and Biochemical Parameters of COVID-19 Patients: A Clinical Trial Pilot Study Cortés-Algara Alfredo, Cárdenas-Rodríguez Noemí, Reyes-Long Samuel, Ortega-Cuellar Daniel, Ruz-Barros Rodrigo, Mondragón-Terán Paul, et al. (+6)
25 [GO] 2022―Jun―14 Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L Ittipat Meewan, Jacob Kattoula, Julius Y. Kattoula, Danielle Skinner, Pavla Fajtová, Miriam A. Giardini, et al. (+5)
26 [GO] 2022―Jun―14 Computational Investigations of Traditional Chinese Medicinal Compounds against the Omicron Variant of SARS-CoV-2 to Rescue the Host Immune System Ziad Tareq Naman, Salim Kadhim, Zahraa J. K. Al-Isawi, Christopher J. Butch, Ziyad Tariq Muhseen
27 [GO] 2022―Jun―13 Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19? Beata Franczyk, Jacek Rysz, Jarosław Miłoński, Tomasz Konecki, Magdalena Rysz-Górzyńska, Anna Gluba-Brzózka
28 [GO] 2022―Jun―04 Protocetraric and Salazinic Acids as Potential Inhibitors of SARS-CoV-2 3CL Protease: Biochemical, Cytotoxic, and Computational Characterization of Depsidones as Slow-Binding Inactivators Lorenza Fagnani, Lisaurora Nazzicone, Pierangelo Bellio, Nicola Franceschini, Donatella Tondi, Andrea Verri, et al. (+5)
29 [GO] 2022―Jun―01 Analgesics Induce Alterations in the Expression of SARS-CoV-2 Entry and Arachidonic-Acid-Metabolizing Genes in the Mouse Lungs Fatima Khirfan, Yazun Jarrar, Tariq Al-Qirim, Khang Wen Goh, Qais Jarrar, Chrismawan Ardianto, et al. (+5)
30 [GO] 2022―May―30 Accurate Mass Identification of an Interfering Water Adduct and Strategies in Development and Validation of an LC-MS/MS Method for Quantification of MPI8, a Potent SARS-CoV-2 Main Protease Inhibitor, in Rat Plasma in Pharmacokinetic Studies Yang Wang, Huan Xie, Yugendar R. Alugubelli, Yuying Ma, Shiqing Xu, Jing Ma, et al. (+2)
31 [GO] 2022―May―30 European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events Gabriella di Mauro, Annamaria Mascolo, Miriam Longo, Maria Ida Maiorino, Lorenzo Scappaticcio, Giuseppe Bellastella, et al. (+2)
32 [GO] 2022―May―21 Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review Sergio Marin, Alba Martin Val, Maite Bosch Peligero, Cristina Rodríguez-Bernuz, Ariadna Pérez-Ricart, Laia Vilaró Vilaró Jaques, et al. (+3)
33 [GO] 2022―May―19 Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19 Sung-Ting Chuang, Henrietta Papp, Anett Kuczmog, Rebecca Eells, Jose M. Condor Capcha, Lina A. Shehadeh, et al. (+2)
34 [GO] 2022―May―18 Discovery of Natural Lead Compound from Dendrobium sp. against SARS-CoV-2 Infection Jutamas Jiaranaikulwanitch, Wipawadee Yooin, Nopporn Chutiwitoonchai, Worathat Thitikornpong, Boonchoo Sritularak, Pornchai Rojsitthisak, Opa Vajragupta
35 [GO] 2022―May―17 Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative? Yadira Palacios, Leslie Chavez-Galan
36 [GO] 2022―May―17 Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity Kelsey E. Huntington, Lindsey Carlsen, Eui-Young So, Matthias Piesche, Olin Liang, Wafik S. El-Deiry
37 [GO] 2022―Apr―28 Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CLpro Main Protease Barbara Herlah, Andrej Hoivik, Luka Jamšek, Katja Valjavec, Norio Yamamoto, Tyuji Hoshino, et al. (+2)
38 [GO] 2022―Apr―28 Design of D-Amino Acids SARS-CoV-2 Main Protease Inhibitors Using the Cationic Peptide from Rattlesnake Venom as a Scaffold Raphael J. Eberle, Ian Gering, Markus Tusche, Philipp N. Ostermann, Lisa Müller, Ortwin Adams, et al. (+6)
39 [GO] 2022―Apr―26 Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines Concetta Rafaniello, Mario Gaio, Alessia Zinzi, Maria Giuseppa Sullo, Valerio Liguori, Marialuisa Ferraro, et al. (+7)
40 [GO] 2022―Apr―26 Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2 Fakry F. Mohamed, Darisuren Anhlan, Michael Schöfbänker, André Schreiber, Nica Classen, Andreas Hensel, et al. (+5)
41 [GO] 2022―Apr―03 Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants Océane Delandre, Mathieu Gendrot, Priscilla Jardot, Marion Le Bideau, Manon Boxberger, Céline Boschi, et al. (+6)
42 [GO] 2022―Mar―25 Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2 Anamika Singh, Isaiah T. Arkin
43 [GO] 2022―Mar―22 Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension Gwenolé Loas, Philippe Van de Borne, Gil Darquennes, Pascal Le Corre
44 [GO] 2022―Mar―21 Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells Nada Amri, Rémi Bégin, Nolwenn Tessier, Laurent Vachon, Louis Villeneuve, Philippe Bégin, et al. (+3)
45 [GO] 2022―Mar―21 One-Pot Synthesis and Molecular Modeling Studies of New Bioactive Spiro-Oxindoles Based on Uracil Derivatives as SARS-CoV-2 Inhibitors Targeting RNA Polymerase and Spike Glycoprotein Samar A. El-Kalyoubi, Ahmed Ragab, Ola A. Abu Abu Ali, Yousry A. Ammar, Mohamed G. Seadawy, Aya Ahmed, Eman A. Fayed
46 [GO] 2022―Mar―14 Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial Irina Karosanidze, Ushangi Kiladze, Nino Kirtadze, Mikhail Giorgadze, Nana Amashukeli, Nino Parulava, et al. (+12)
47 [GO] 2022―Mar―09 COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy Alexander Domnich, Andrea Orsi, Carlo-Simone Trombetta, Giulia Guarona, Donatella Panatto, Giancarlo Icardi
48 [GO] 2022―Mar―09 From Biomedical Applications of Alginate towards CVD Implications Linked to COVID-19 Angela Spoială, Cornelia-Ioana Ilie, Denisa Ficai, Anton Ficai, Ecaterina Andronescu
49 [GO] 2022―Mar―03 Vitamin D Status and Immune Response in Hospitalized Patients with Moderate and Severe COVID-19 Tatiana L. Karonova, Igor V. Kudryavtsev, Ksenia A. Golovatyuk, Arthur D. Aquino, Olga V. Kalinina, Alena T. Chernikova, et al. (+5)
50 [GO] 2022―Feb―22 Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application Jean Claude Alvarez, Benjamin Davido, Pierre Moine, Isabelle Etting, Djillali Annane, Islam Amine Larabi, Nicolas Simon
51 [GO] 2022―Feb―21 Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case-Control Study Maria Albanese, Giulia Marrone, Agostino Paolino, Manuela Di Di Lauro, Francesca Di Di Daniele, Carlo Chiaramonte, et al. (+8)
52 [GO] 2022―Feb―07 Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial Katarzyna Kotfis, Igor Karolak, Kacper Lechowicz, Małgorzata Zegan-Barańska, Agnieszka Pikulska, Paulina Niedźwiedzka-Rystwej, et al. (+4)
53 [GO] 2022―Feb―07 Dementia and COVID-19: A Case Report and Literature Review on Pain Management Damiana Scuteri, Marianna Contrada, Paolo Tonin, Maria Tiziana Corasaniti, Pierluigi Nicotera, Giacinto Bagetta
54 [GO] 2022―Feb―02 Re-Exploring the Ability of Common Docking Programs to Correctly Reproduce the Binding Modes of Non-Covalent Inhibitors of SARS-CoV-2 Protease Mpro Davide Bassani, Matteo Pavan, Giovanni Bolcato, Mattia Sturlese, Stefano Moro
55 [GO] 2022―Jan―29 Novel Small-Molecule Inhibitors of the SARS-CoV-2 Spike Protein Binding to Neuropilin 1 Anja Kolarič, Marko Jukič, Urban Bren
56 [GO] 2022―Jan―28 Exploring Toxins for Hunting SARS-CoV-2 Main Protease Inhibitors: Molecular Docking, Molecular Dynamics, Pharmacokinetic Properties, and Reactome Study Mahmoud A. A. Ibrahim, Alaa H. M. Abdelrahman, Laila A. Jaragh-Alhadad, Mohamed A. M. Atia, Othman R. Alzahrani, Muhammad Naeem Ahmed, et al. (+6)
57 [GO] 2022―Jan―24 Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants Riadh Badraoui, Mongi Saoudi, Walid S. Hamadou, Salem Elkahoui, Arif J. Siddiqui, Jahoor M. Alam, et al. (+7)
58 [GO] 2022―Jan―10 A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis Jaime Monserrat Villatoro, Gina Mejía-Abril, Lucía Díaz García, Pablo Zubiaur, María Jiménez González, Guillermo Fernandez Jimenez, et al. (+11)
59 [GO] 2021―Dec―27 Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin Joaquim Bosch-Barrera, Ariadna Roqué, Eduard Teixidor, Maria Carmen Carmona-Garcia, Aina Arbusà, Joan Brunet, et al. (+4)
60 [GO] 2021―Dec―27 Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo Otávio Augusto Chaves, Carolina Q. Sacramento, André C. Ferreira, Mayara Mattos, Natalia Fintelman-Rodrigues, Jairo R. Temerozo, et al. (+12)
61 [GO] 2021―Dec―20 Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office Diego Alejandro Dri, Giulia Praticò, Elisa Gaucci, Carlotta Marianecci, Donatella Gramaglia
62 [GO] 2021―Dec―20 Inhibition Ability of Natural Compounds on Receptor-Binding Domain of SARS-CoV2: An In Silico Approach Miroslava Nedyalkova, Mahdi Vasighi, Subrahmanyam Sappati, Anmol Kumar, Sergio Madurga, Vasil Simeonov
63 [GO] 2021―Dec―17 Promising Antiviral Activity of Agrimonia pilosa Phytochemicals against Severe Acute Respiratory Syndrome Coronavirus 2 Supported with In Vivo Mice Study Nashwah G. M. Attallah, Aya H. El-Kadem, Walaa A. Negm, Engy Elekhnawy, Thanaa A. El-Masry, Elshaymaa I. Elmongy, et al. (+4)
64 [GO] 2021―Dec―07 Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives Eugenia Quiros-Roldan, Silvia Amadasi, Isabella Zanella, Melania Degli Antoni, Samuele Storti, Giorgio Tiecco, Francesco Castelli
65 [GO] 2021―Dec―03 Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists Mai Kawazoe, Mari Kihara, Toshihiro Nanki
66 [GO] 2021―Dec―01 Teicoplanin-A New Use for an Old Drug in the COVID-19 Era? Vladimir Vimberg
67 [GO] 2021―Dec―01 Computational and In Vitro Experimental Investigations Reveal Anti-Viral Activity of Licorice and Glycyrrhizin against Severe Acute Respiratory Syndrome Coronavirus 2 Ahmed M. Tolah, Lamya M. Altayeb, Thamir A. Alandijany, Vivek Dhar Dwivedi, Sherif A. El-Kafrawy, Esam I. Azhar
68 [GO] 2021―Dec―01 Discovery of SARS-CoV-2 Nsp14 and Nsp16 Methyltransferase Inhibitors by High-Throughput Virtual Screening Raitis Bobrovs, Iveta Kanepe, Nauris Narvaiss, Liene Patetko, Gints Kalnins, Mihails Sisovs, et al. (+8)
69 [GO] 2021―Nov―17 Brief on Recent Application of Liposomal Vaccines for Lower Respiratory Tract Viral Infections: From Influenza to COVID-19 Vaccines Mohamed Ahmed Attia, Ebtessam Ahmed Essa, Toka Tarek Elebyary, Ahmed Mostafa Faheem, Amal Ali Elkordy
70 [GO] 2021―Nov―12 An Evaluation of the Potential of Essential Oils against SARS-CoV-2 from In Silico Studies through the Systematic Review Using a Chemometric Approach Luiz Torres Neto, Maria Lúcia Guerra Monteiro, Diego Galvan, Carlos Adam Conte-Junior
71 [GO] 2021―Nov―12 Investigation of Thiocarbamates as Potential Inhibitors of the SARS-CoV-2 Mpro Katarzyna Papaj, Patrycja Spychalska, Katarzyna Hopko, Patryk Kapica, Andre Fisher, Markus A. Lill, et al. (+6)
72 [GO] 2021―Nov―09 Regulation of m6A Methylation as a New Therapeutic Option against COVID-19 Carla Zannella, Luca Rinaldi, Giovanni Boccia, Annalisa Chianese, Ferdinando Carlo Sasso, Francesco De Caro, et al. (+2)
73 [GO] 2021―Nov―02 Natural Apocarotenoids and Their Synthetic Glycopeptide Conjugates Inhibit SARS-CoV-2 Replication Ilona Bereczki, Henrietta Papp, Anett Kuczmog, Mónika Madai, Veronika Nagy, Attila Agócs, et al. (+15)
74 [GO] 2021―Oct―18 The Impact of SARS-CoV-2 Infection, and Application of Immunosuppressive Agents in Kidney Transplant Recipients Suffering from COVID-19 Horng-Ta Tseng, Xiang-Chi Wu, Chun-Yao Huang, Chun-Ming Shih, Yi-Wen Lin, Feng-Yen Lin
75 [GO] 2021―Oct―18 Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18-30 Years Old): An Independent Post-Marketing Study Abanoub Riad, Andrea Pokorná, Jitka Klugarová, Natália Antalová, Lucia Kantorová, Michal Koščík, Miloslav Klugar
76 [GO] 2021―Oct―18 SARS-CoV-2 Fears Green: The Chlorophyll Catabolite Pheophorbide A Is a Potent Antiviral Guillermo H. Jimenez-Aleman, Victoria Castro, Addis Londaitsbehere, Marta Gutierrez-Rodríguez, Urtzi Garaigorta, Roberto Solano, Pablo Gastaminza
77 [GO] 2021―Oct―18 In Vitro Effect of Taraxacum officinale Leaf Aqueous Extract on the Interaction between ACE2 Cell Surface Receptor and SARS-CoV-2 Spike Protein D614 and Four Mutants Hoai Thi Thu Tran, Michael Gigl, Nguyen Phan Khoi Le, Corinna Dawid, Evelyn Lamy
78 [GO] 2021―Oct―09 Targeting SARS-CoV-2 Variants with Nucleic Acid Therapeutic Nanoparticle Conjugates Hanah F. Huber, Majid Jaberi-Douraki, Sarah DeVader, Cesar Aparicio-Lopez, Juliet Nava-Chavez, Xuan Xu, et al. (+3)
79 [GO] 2021―Sep―28 Ginkgolic Acid Inhibits Coronavirus Strain 229E Infection of Human Epithelial Lung Cells Maimoona Bhutta, Daniel Sausen, Elisa Gallo, Harel Dahari, Gustavo Doncel, Ronen Borenstein
80 [GO] 2021―Sep―24 Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19 Jen-Yu Hsu, Yan-Chiao Mao, Po-Yu Liu, Kuo-Lung Lai
81 [GO] 2021―Sep―24 A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2) Paolo Coghi, Li Jun Yang, Jerome P. L. Ng, Richard K. Haynes, Maurizio Memo, Alessandra Gianoncelli, et al. (+2)
82 [GO] 2021―Sep―18 Neuropsychiatric Disorders and COVID-19: What We Know So Far Fernanda Majolo, Guilherme Liberato da Silva, Lucas Vieira, Cetin Anli, Luís Fernando Saraiva Macedo Timmers, Stefan Laufer, Márcia Inês Goettert
83 [GO] 2021―Sep―06 In Silico Prediction of Novel Inhibitors of SARS-CoV-2 Main Protease through Structure-Based Virtual Screening and Molecular Dynamic Simulation Sobia Ahsan Halim, Muhammad Waqas, Ajmal Khan, Ahmed Al-Harrasi
84 [GO] 2021―Sep―03 Sub-Micromolar Inhibition of SARS-CoV-2 3CLpro by Natural Compounds Bruno Rizzuti, Laura Ceballos-Laita, David Ortega-Alarcon, Ana Jimenez-Alesanco, Sonia Vega, Fedora Grande, et al. (+3)
85 [GO] 2021―Sep―01 Synthesis and Biological Evaluation of Honokiol Derivatives Bearing 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3H)-ones as Potential Viral Entry Inhibitors against SARS-CoV-2 Yong Guo, Jie-Ru Meng, Jia-Zheng Liu, Ting Xu, Zhi-Yuan Zheng, Zhi-Hong Jiang, Li-Ping Bai
86 [GO] 2021―Aug―31 Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia Abanoub Riad, Barbora Hocková, Lucia Kantorová, Rastislav Slávik, Lucia Spurná, Adam Stebel, et al. (+2)
87 [GO] 2021―Aug―23 Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic José M. Serra López-Matencio, Manuel Gómez, Esther F. Vicente-Rabaneda, Miguel A. González-Gay, Julio Ancochea, Santos Castañeda
88 [GO] 2021―Aug―23 Correction: Zanella et al. Tenofovir, Another Inexpensive, Well Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals 2021, 14, 454 Isabella Zanella, Daniela Zizioli, Francesco Castelli, Eugenia Quiros-Roldan
89 [GO] 2021―Aug―18 Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Enrique Ambrocio-Ortiz, Gloria Pérez-Rubio, Alma D. Del Ángel-Pablo, Ivette Buendía-Roldán, Leslie Chávez-Galán, Rafael de Jesús Hernández-Zenteno, et al. (+6)
90 [GO] 2021―Aug―18 Lung Fibrosis after COVID-19: Treatment Prospects Evgeny Bazdyrev, Polina Rusina, Maria Panova, Fedor Novikov, Ivan Grishagin, Vladimir Nebolsin
91 [GO] 2021―Aug―04 Prevalence and Significance of Hypermetabolic Lymph Nodes Detected by 2-[18F]FDG PET/CT after COVID-19 Vaccination: A Systematic Review and a Meta-Analysis Giorgio Treglia, Marco Cuzzocrea, Luca Giovanella, Luigia Elzi, Barbara Muoio
92 [GO] 2021―Aug―02 Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease Swayam Prakash Srivastava, Rohit Srivastava, Subhash Chand, Julie E. Goodwin
93 [GO] 2021―Jul―30 Reynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors-Molecular Docking and In Vitro Study Izabela Nawrot-Hadzik, Mikolaj Zmudziński, Adam Matkowski, Robert Preissner, Małgorzata Kęsik-Brodacka, Jakub Hadzik, et al. (+2)
94 [GO] 2021―Jul―28 Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues Milo Gatti, Eleonora Turrini, Emanuel Raschi, Piero Sestili, Carmela Fimognari
95 [GO] 2021―Jul―28 Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review Victoria Gil Martínez, Ana Avedillo Salas, Sonia Santander Ballestín
96 [GO] 2021―Jul―19 Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection Gwenolé Loas, Pascal Le Corre
97 [GO] 2021―Jul―19 Soluble Angiotensin Converting Enzyme 2 (ACE2) Is Upregulated and Soluble Endothelial Nitric Oxide Synthase (eNOS) Is Downregulated in COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) Alice G. Vassiliou, Alexandros Zacharis, Chrysi Keskinidou, Edison Jahaj, Maria Pratikaki, Parisis Gallos, et al. (+3)
98 [GO] 2021―Jul―16 Current Status of Baricitinib as a Repurposed Therapy for COVID-19 Maha Saber-Ayad, Sarah Hammoudeh, Eman Abu-Gharbieh, Rifat Hamoudi, Hamadeh Tarazi, Taleb H. Al-Tel, Qutayba Hamid
99 [GO] 2021―Jul―15 Use of Monoclonal Antibody to Treat COVID-19 in Children and Adolescents: Risk of Abuse of Prescription and Exacerbation of Health Inequalities Susanna Esposito, Stefano Zona, Andrea Pession, Lorenzo Iughetti, Giovanni Battista Migliori, Nicola Principi
100 [GO] 2021―Jul―12 COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes? Jean Jacques Vanden Eynde
101 [GO] 2021―Jun―23 Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library Prabhat Pratap Singh Tomar, Miriam Krugliak, Isaiah T. Arkin
102 [GO] 2021―Jun―07 Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 MPro Inhibitor Hani A. Alhadrami, Ahmed M. Sayed, Heba Al-Khatabi, Nabil A. Alhakamy, Mostafa E. Rateb
103 [GO] 2021―May―31 Clinical Management of COVID-19: A Review of Pharmacological Treatment Options Ashli M. Heustess, Melissa A. Allard, Dorothea K. Thompson, Pius S. Fasinu
104 [GO] 2021―May―27 Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection Sherif A. El-Kafrawy, Aymn T. Abbas, Sayed S. Sohrab, Ashraf A. Tabll, Ahmed M. Hassan, Naoko Iwata-Yoshikawa, et al. (+2)
105 [GO] 2021―May―26 New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection Bauso Luana Vittoria, Chiara Imbesi, Gasparo Irene, Gabriella Calì, Alessandra Bitto
106 [GO] 2021―May―20 Hydrotalcite-Niclosamide Nanohybrid as OralFormulation towards SARS-CoV-2 Viral Infections Goeun Choi, Huiyan Piao, N. Sanoj Rejinold, Seungjin Yu, Ki yeok Kim, Geun-woo Jin, Jin-Ho Choy
107 [GO] 2021―May―11 Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection Isabella Zanella, Daniela Zizioli, Francesco Castelli, Eugenia Quiros-Roldan
108 [GO] 2021―Apr―26 COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials Zhi-Peng Yan, Ming Yang, Ching-Lung Lai
109 [GO] 2021―Apr―06 Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients Annalisa Noce, Maria Albanese, Giulia Marrone, Manuela Di Lauro, Anna Pietroboni Zaitseva, Daniela Palazzetti, et al. (+9)
110 [GO] 2021―Apr―06 Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods Tiziana Ginex, Urtzi Garaigorta, David Ramírez, Victoria Castro, Vanesa Nozal, Inés Maestro, et al. (+5)
111 [GO] 2021―Mar―31 Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids Gill Diamond, Natalia Molchanova, Claudine Herlan, John A. Fortkort, Jennifer S. Lin, Erika Figgins, et al. (+6)
112 [GO] 2021―Mar―08 Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study Gil Darquennes, Pascal Le Corre, Olivier Le Moine, Gwenolé Loas
113 [GO] 2021―Mar―05 Rapamycin: Drug Repurposing in SARS-CoV-2 Infection Jiri Patocka, Kamil Kuca, Patrik Oleksak, Eugenie Nepovimova, Martin Valis, Michal Novotny, Blanka Klimova
114 [GO] 2021―Mar―05 Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches Hossam M. Abdallah, Ali M. El-Halawany, Alaa Sirwi, Amr M. El-Araby, Gamal A. Mohamed, Sabrin R. M. Ibrahim, et al. (+4)
115 [GO] 2021―Feb―25 Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus Nabil A. Alhakamy, Osama A. A. Ahmed, Tarek S. Ibrahim, Hibah M. Aldawsari, Khalid Eljaaly, Usama A. Fahmy, et al. (+3)
116 [GO] 2021―Jan―25 Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach Andrea Gelemanović, Tinka Vidović, Višnja Stepanić, Katarina Trajković
117 [GO] 2021―Jan―20 COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis, Kacper Lechowicz, Sylwester Drożdżal, Paulina Niedźwiedzka-Rystwej, Tomasz K. Wojdacz, Ewelina Grywalska, et al. (+3)
118 [GO] 2021―Jan―11 Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection Praveen P. N. Rao, Amy Trinh Pham, Arash Shakeri, Amna El Shatshat, Yusheng Zhao, Rahul C. Karuturi, Ahmed A. Hefny
119 [GO] 2021―Jan―07 Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2 Iman Almansour, Nabela Calamata Macadato, Thamer Alshammari
120 [GO] 2020―Dec―28 Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19 Cara A. Timpani, Emma Rybalka
121 [GO] 2020―Dec―08 Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules Kenana Al Adem, Aya Shanti, Cesare Stefanini, Sungmun Lee
122 [GO] 2020―Dec―04 FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2 Ahmed Mostafa, Ahmed Kandeil, Yaseen A. M. M. Elshaier, Omnia Kutkat, Yassmin Moatasim, Adel A. Rashad, et al. (+14)
123 [GO] 2020―Nov―28 Emetine Is Not Ipecac: Considerations for Its Use as Treatment for SARS-CoV2 Martin D. Bleasel, Gregory M. Peterson
124 [GO] 2020―Nov―27 Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics Anna Maria Piras, Ylenia Zambito, Maurizio Lugli, Baldassare Ferro, Paolo Roncucci, Filippo Mori, et al. (+4)
125 [GO] 2020―Nov―10 Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review Salvatore Annunziata, Roberto C. Delgado Bolton, Christel-Hermann Kamani, John O. Prior, Domenico Albano, Francesco Bertagna, Giorgio Treglia
126 [GO] 2020―Oct―17 Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study Benjamin Rossi, Lee S. Nguyen, Philippe Zimmermann, Faiza Boucenna, Louis Dubret, Louise Baucher, et al. (+7)
127 [GO] 2020―Oct―16 Medicinal Plants to Strengthen Immunity during a Pandemic Olga Babich, Stanislav Sukhikh, Alexander Prosekov, Lyudmila Asyakina, Svetlana Ivanova
128 [GO] 2020―Sep―09 Can Nuclear Imaging of Activated Macrophages with Folic Acid-Based Radiotracers Serve as a Prognostic Means to Identify COVID-19 Patients at Risk? Cristina Müller, Roger Schibli, Britta Maurer
129 [GO] 2020―Sep―01 Zinc(II)-The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19? Aleksandra Hecel, Małgorzata Ostrowska, Kamila Stokowa-Sołtys, Joanna Wątły, Dorota Dudek, Adriana Miller, et al. (+5)
130 [GO] 2020―Aug―10 Emerging Therapeutic Modalities against COVID-19 Shipra Malik, Anisha Gupta, Xiaobo Zhong, Theodore P. Rasmussen, Jose E. Manautou, Raman Bahal
131 [GO] 2020―Jul―28 Squalene Emulsion Manufacturing Process Scale-Up for Enhanced Global Pandemic Response Tony Phan, Christian Devine, Erik D. Laursen, Adrian Simpson, Aaron Kahn, Amit P. Khandhar, et al. (+5)
132 [GO] 2020―Jul―27 Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence? Mikhail Kiselevskiy, Irina Shubina, Irina Chikileva, Suria Sitdikova, Igor Samoylenko, Natalia Anisimova, et al. (+4)
133 [GO] 2020―Jul―20 Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications Yufeng Wei, Rameen Shah
134 [GO] 2020―Jul―06 Cancer Patients Have a Higher Risk Regarding COVID-19 - and Vice Versa? Franz Geisslinger, Angelika M. Vollmar, Karin Bartel
135 [GO] 2020―Jun―25 Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection Andreia Palmeira, Emília Sousa, Aylin Köseler, Ramazan Sabirli, Tarık Gören, İbrahim Türkçüer, et al. (+3)
136 [GO] 2020―May―14 The Rationale for Potential Pharmacotherapy of COVID-19 Maha Saber-Ayad, Mohamed A. Saleh, Eman Abu-Gharbieh
137 [GO] 2020―May―14 COVID-19: An Update About the Discovery Clinical Trial Jean Jacques Vanden Eynde
138 [GO] 2020―Apr―13 COVID-19: A Brief Overview of the Discovery Clinical Trial Jean Jacques Vanden Eynde
139 [GO] 2020―Mar―23 Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses Martin D Bleasel, Gregory M Peterson
 [1] 

139 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.045 sec